Association of activated partial thromboplastin time and fibrinogen level in patients with type II diabetes mellitus

BMC Research Notes

Sunil Poudel¹  Saroj Kumar Shrestha¹  Binaya Sapkota² 

[1] Government of Nepal Civil Service Hospital, Minbhawan, Kathmandu, Nepal;Kathmandu University School of Science, Dhulikhel, Kavre, Nepal

关键词: Fibrinogen;    Diabetes mellitus;    Activated partial thromboplastin time;   

Others  :  1140685
DOI  :  10.1186/1756-0500-6-485

 received in 2013-09-12, accepted in 2013-11-23,  发布年份 2013

【 摘 要 】

Background

Patients with diabetes mellitus have a high risk of atherothrombotic events. Diabetes contributes for initiation and progression of microvascular and macrovascular complications. Shortened activated partial thromboplastin time (aPTT) values may reflect hypercoaguable state, which is associated with increased thrombotic risk and adverse cardiovascular events. Increased level of fibrinogen is common in type II diabetes. The present study was conducted to study the aPTT and fibrinogen levels in diabetics in a tertiary care Teaching Hospital of Nepal.

Methods

Observational study was performed at out-patients visiting Pathology Department at Tribhuvan University Teaching Hospital from August 5 to September 7, 2012. Research protocol was approved by Institutional Review Board at Tribhuvan University Institute of Medicine. Altogether 90 people who came to the hospital during study period and who met inclusion criteria were selected, out of which 72 were diabetics and 18 were normal controls. Diabetic cases were identified via verbal interview with patients themselves and review of laboratory findings and diagnosis performed by their physicians. Diabetics with a diabetic history of more than one year and stabilized with antidiabetic medicines such as insulin, metformin, glibenclamide, and gliclazide and diabetics with controlled diabetes as revealed by HbA_1c in the range 6.2-7% were taken for the study purpose. Data were analyzed with chi square test and Fischer’s exact test (when each cell frequency was less than 5) using Statistical Package for Social Sciences 17.

Results

Maximum (53; 73.6%) diabetics and all non-diabetics had aPTT in the range 26–40 seconds. Maximum (51; 70.8%) patients had fibrinogen beyond 351 whereas all non-diabetics had fibrinogen in the range 151–350. Mean aPTT values of the diabetic patients and non-diabetic persons were 29.88 ± 4.89 seconds and 32.44 ± 2.25 seconds respectively. Mean fibrinogen values of the diabetic patients and non-diabetic persons were 388.57 ± 60.90 mg/dL and 320.89 ± 10.20 mg/dL respectively. Test data identified in results were statistically significant for aPTT (p value 0.000) and fibrinogen (p value 0.000) between the diabetics and non-diabetics.

Conclusions

Diabetics have an increased level of fibrinogen and relatively shortened aPTT as compared to the non-diabetic patients.

【 授权许可】

   
2013 Sapkota et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Clement S, Braithwaite SS, Magee MF, Ahmann A, Smith EP, Schafer RG, Hirsch IB: Management of diabetes and hyperglycemia in hospitals. Diabetes Care 2004, 27:553-591.
• [2]Lemkes BA, Hermanides J, Devries JH, Holleman F, Meijers JCM, Hoekstra JBL: Hyperglycemia: a prothrombotic factor? J Thromb Haemost 2010, 8:1663-1669.
• [3]Maritim AC, Sanders RA, Watkins JB: Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 2003, 17:24-38.
• [4]Lippi G, Franchini M, Targher G, Montagnana M, Salvagno GL, Guidi GC, Favaloro EJ: Epidemiological association between fasting plasma glucose and shortened APTT. Clin Biochem 2009, 42:118-120.
• [5]Barazzoni R, Zanetti M, Davanzo G, Kiwanuka E, Carraro P, Tiengo A, Tessari P: Increased fibrinogen production in type 2 diabetic patients without detectable vascular complications: Correlation with plasma glucagon concentrations. J Clin Endocrinol Metab 2000, 85:3121-3125.
• [6]Mina A, Favaloro EJ, Mohammed S, Koutts J: A laboratory evaluation into the short activated partial thromboplastin time. Blood Coagul Fibrinolysis 2010, 21:152-157.
• [7]Tripodi A, Chantarangkul V, Martinelli I, Bucciarelli P, Mannucci PM: A shortened activated partial thromboplastin time is associated with the risk of venous thromboembolism. Blood 2004, 104:3631-3634.
• [8]Grant PJ: Diabetes mellitus as a prothrombotic condition. J Intern Med 2007, 262:157-172.
• [9]Reddy NM, Hall SW, Mackintosh FR: Partial thromboplastin time: prediction of adverse events and poor prognosis by low abnormal values. Arch Intern Med 1999, 159:2706-2710.
• [10]Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs R, Vuksan V, Teo K, Davis B, Montague P, Yusuf S: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 2003, 108:420-425.
• [11]Jones RL, Peterson CM: Reduced fibrinogen survival in diabetes mellitus: a reversible phenomenon. J Clin Invest 1979, 63:485-493.
• [12]Ceriello A, Giacomello R, Stel G, Motz E, Taboga C, Tonutti L, Pirisi M, Falleti E, Bartoli E: Hyperglycemia-induced thrombin formation in diabetes: the possible role of oxidative stress. Diabetes 1995, 44:924-928.
• [13]Zhao Y, Zhang J, Zhang J, Wu J: Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One 2011, 6:1-4.
• [14]Festa A, D’Agostino R, Tracy RP, Haffner SM: Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 2002, 51:1131-1137.
• [15]Korte W, Clarke S, Lefkowitz JB: Short activated partial thromboplastin times are related to increased thrombin generation and an increased risk for thromboembolism. Am J Clin Pathol 2000, 113:123-127.
• [16]Lippi G, Salvagno GL, Ippolito L, Franchini M, Favaloro EJ: Shortened activated partial thromboplastin time: causes and management. Blood Coagul Fibrinolysis 2010, 21:459-463.